2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Interventions
pembrolizumab
189
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
durvalumab
5
belzutifan
5
Nivolumab
5
Dexamethasone
5
Surgical Procedures, Operative
4
Radiotherapy
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Histamine Antagonists
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled